BridgeBio Pharma (NASDAQ:BBIO) Price Target Raised to $56.00

BridgeBio Pharma (NASDAQ:BBIO) had its target price raised by HC Wainwright from $53.00 to $56.00 in a research report report published on Monday,Benzinga reports. The firm currently has a buy rating on the stock. HC Wainwright also issued estimates for BridgeBio Pharma’s Q2 2025 earnings at ($0.87) EPS, Q3 2025 earnings at ($0.84) EPS, Q4 2025 earnings at ($0.85) EPS, FY2025 earnings at ($3.44) EPS, Q1 2026 earnings at ($0.69) EPS, Q2 2026 earnings at ($0.60) EPS, Q3 2026 earnings at ($0.50) EPS, Q4 2026 earnings at ($0.32) EPS and FY2026 earnings at ($2.10) EPS.

Other equities research analysts also recently issued reports about the company. Citigroup upped their target price on BridgeBio Pharma from $45.00 to $49.00 and gave the company a “buy” rating in a report on Friday, February 21st. Redburn Atlantic started coverage on BridgeBio Pharma in a report on Monday, March 31st. They set a “buy” rating and a $50.00 price objective on the stock. Scotiabank raised their target price on BridgeBio Pharma from $52.00 to $55.00 and gave the company a “sector outperform” rating in a report on Wednesday, April 30th. UBS Group lifted their price objective on BridgeBio Pharma from $65.00 to $72.00 and gave the stock a “buy” rating in a report on Wednesday, April 30th. Finally, Piper Sandler raised their target price on BridgeBio Pharma from $46.00 to $63.00 and gave the stock an “overweight” rating in a research report on Wednesday, April 30th. Two investment analysts have rated the stock with a hold rating and eleven have given a buy rating to the company’s stock. Based on data from MarketBeat, BridgeBio Pharma has an average rating of “Moderate Buy” and an average target price of $57.36.

BridgeBio Pharma Trading Down 2.6%

Shares of BridgeBio Pharma stock opened at $39.05 on Monday. The business’s fifty day moving average price is $34.92 and its 200 day moving average price is $32.91. The stock has a market capitalization of $7.41 billion, a P/E ratio of -13.70 and a beta of 1.10. BridgeBio Pharma has a twelve month low of $21.62 and a twelve month high of $40.40.

BridgeBio Pharma (NASDAQ:BBIO) last issued its quarterly earnings results on Tuesday, April 29th. The company reported ($0.88) earnings per share for the quarter, beating analysts’ consensus estimates of ($1.00) by $0.12. The firm had revenue of $36.74 million during the quarter, compared to the consensus estimate of $57.14 million. BridgeBio Pharma’s revenue was down 44.8% compared to the same quarter last year. During the same quarter last year, the firm posted ($0.20) earnings per share. As a group, sell-side analysts predict that BridgeBio Pharma will post -3.67 EPS for the current year.

Insider Activity at BridgeBio Pharma

In other BridgeBio Pharma news, CAO Maricel Apuli sold 1,026 shares of the business’s stock in a transaction on Friday, May 2nd. The shares were sold at an average price of $38.51, for a total value of $39,511.26. Following the sale, the chief accounting officer now owns 147,639 shares in the company, valued at $5,685,577.89. The trade was a 0.69% decrease in their position. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available through the SEC website. Also, Director Hannah Valantine sold 4,292 shares of the company’s stock in a transaction dated Tuesday, June 10th. The shares were sold at an average price of $40.00, for a total transaction of $171,680.00. Following the transaction, the director now owns 1,764 shares in the company, valued at $70,560. The trade was a 70.87% decrease in their ownership of the stock. The disclosure for this sale can be found here. Insiders have sold a total of 6,396,474 shares of company stock valued at $219,332,971 over the last 90 days. 18.20% of the stock is owned by insiders.

Institutional Inflows and Outflows

Several institutional investors have recently made changes to their positions in BBIO. Steward Partners Investment Advisory LLC grew its position in shares of BridgeBio Pharma by 85.8% in the fourth quarter. Steward Partners Investment Advisory LLC now owns 1,022 shares of the company’s stock valued at $28,000 after purchasing an additional 472 shares during the period. GAMMA Investing LLC raised its stake in BridgeBio Pharma by 71.0% during the first quarter. GAMMA Investing LLC now owns 920 shares of the company’s stock worth $32,000 after purchasing an additional 382 shares during the period. Jones Financial Companies Lllp purchased a new position in BridgeBio Pharma during the first quarter worth about $35,000. Itau Unibanco Holding S.A. purchased a new position in BridgeBio Pharma during the fourth quarter worth about $41,000. Finally, Sterling Capital Management LLC raised its stake in shares of BridgeBio Pharma by 554.6% in the 4th quarter. Sterling Capital Management LLC now owns 1,787 shares of the company’s stock valued at $49,000 after acquiring an additional 1,514 shares during the period. Hedge funds and other institutional investors own 99.85% of the company’s stock.

BridgeBio Pharma Company Profile

BridgeBio Pharma, Inc, a commercial-stage biopharmaceutical company, discovers, creates, tests, and delivers transformative medicines to treat patients who suffer from genetic diseases and cancers. Its products in development programs include AG10, a next-generation oral small molecule near-complete TTR stabilizer that is in Phase 3 clinical trial for the treatment of TTR amyloidosis, or transthyretin amyloid cardiomyopathy (ATTR-CM); low-dose infigratinib, an oral FGFR1-3 selective tyrosine kinase inhibitor, which is in Phase 3 double-blinded, placebo-controlled pivotal study for the treatment option for children with achondroplasia; and BBP-631, an AAV5 gene transfer product candidate that is in Phase 1/2 clinical trial for the treatment of congenital adrenal hyperplasia, or CAH, driven by 21-hydroxylase deficiency, or 21OHD.